Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of ILS 25.34 million. The enterprise value is 38.02 million.

Market Cap	25.34M
Enterprise Value	38.02M

Important Dates

The next estimated earnings date is Tuesday, May 20, 2025.

Earnings Date	May 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Evogene has 6.51 million shares outstanding. The number of shares has increased by 24.14% in one year.

Current Share Class	n/a
Shares Outstanding	6.51M
Shares Change (YoY)	+24.14%
Shares Change (QoQ)	+17.02%
Owned by Insiders (%)	1.32%
Owned by Institutions (%)	6.67%
Float	6.43M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.82
PB Ratio	0.47
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.63
EV / Sales	1.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.51

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.17.

Current Ratio	1.15
Quick Ratio	0.90
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	-0.12
Interest Coverage	-352.54

Financial Efficiency

Return on equity (ROE) is -82.96% and return on invested capital (ROIC) is -58.86%.

Return on Equity (ROE)	-82.96%
Return on Assets (ROA)	-30.52%
Return on Invested Capital (ROIC)	-58.86%
Return on Capital Employed (ROCE)	-104.92%
Revenue Per Employee	264,954
Profits Per Employee	-513,191
Employee Count	117
Asset Turnover	0.19
Inventory Turnover	2.83

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -83.30% in the last 52 weeks. The beta is 1.18, so Evogene's price volatility has been higher than the market average.

Beta (5Y)	1.18
52-Week Price Change	-83.30%
50-Day Moving Average	475.50
200-Day Moving Average	726.16
Relative Strength Index (RSI)	35.80
Average Volume (20 Days)	61,711

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Evogene had revenue of ILS 31.00 million and -60.04 million in losses. Loss per share was -10.54.

Revenue	31.00M
Gross Profit	21.23M
Operating Income	-80.90M
Pretax Income	-65.73M
Net Income	-60.04M
EBITDA	-74.68M
EBIT	-80.90M
Loss Per Share	-10.54

Full Income Statement

Balance Sheet

The company has 55.77 million in cash and 9.12 million in debt, giving a net cash position of 46.65 million or 7.16 per share.

Cash & Cash Equivalents	55.77M
Total Debt	9.12M
Net Cash	46.65M
Net Cash Per Share	7.16
Equity (Book Value)	54.04M
Book Value Per Share	-0.81
Working Capital	10.54M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -71.75 million and capital expenditures -2.28 million, giving a free cash flow of -74.03 million.

Operating Cash Flow	-71.75M
Capital Expenditures	-2.28M
Free Cash Flow	-74.03M
FCF Per Share	-11.36

Full Cash Flow Statement

Margins

Gross margin is 68.48%, with operating and profit margins of -260.96% and -193.69%.

Gross Margin	68.48%
Operating Margin	-260.96%
Pretax Margin	-212.02%
Profit Margin	-193.69%
EBITDA Margin	-240.90%
EBIT Margin	-260.96%
FCF Margin	n/a

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.14%
Shareholder Yield	-24.14%
Earnings Yield	-236.93%
FCF Yield	-292.14%

Stock Splits

The last stock split was on July 28, 2024. It was a reverse split with a ratio of 0.1.

Last Split Date	Jul 28, 2024
Split Type	Reverse
Split Ratio	0.1

Scores

Evogene has an Altman Z-Score of -10.5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-10.5
Piotroski F-Score	n/a